Christopher Ryan Sullivan

CIK 1810417 · Chief Financial Officer · last filed 2026-05-26

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$595.2K

Companies

2

Total Filings

19

Lifetime Open-Market Net

-$1.87M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AVTX Chief Financial Officer 40,323 $14.76 $595.2K -$1.89M 16 2026-05-26
Avalo Therapeutics, Inc. (CERC) Delisted Interim CFO 8,049 $2.93 $23.6K $18.3K 3 2021-01-28

Recent Filings · Page 2 of 2

19 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2023-06-13 AVTX Buy (P) +511 $1.7K EDGAR
2023-05-17 AVTX Grant (A) $0 EDGAR
2023-02-15 AVTX Grant (A) $0 EDGAR
2022-10-07 AVTX Grant (A) $0 EDGAR
2022-03-10 AVTX Grant (A) $0 EDGAR
2021-12-14 AVTX Buy (P) +955 $1.5K EDGAR
2021-01-28 Avalo Therapeutics, Inc. (CERC) Delisted Grant (A) $0 EDGAR
2020-12-14 Avalo Therapeutics, Inc. (CERC) Delisted Buy (P) +5,095 $11.6K EDGAR
2020-06-11 Avalo Therapeutics, Inc. (CERC) Delisted Buy (P) +2,954 $6.7K EDGAR
Showing 1119 of 19
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.